Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C P Cross

Showing results (111-120 of 221) with videos related to

Pageof 23
Sort By:
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Cancer Research|April 17, 2004
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorderJosé L Vizmanos, Francisco J Novo, José P Román, et al.
Haematologica|October 16, 2012
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblastsVéronique Gelsi-Boyer, Nathalie Cervera, François Bertucci, et al.
Cancer Cell|April 5, 2003
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBPKenji Deguchi, Paul M Ayton, Melina Carapeti, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Haematologica|February 25, 2015
Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisNils Winkelmann, Matthew Rose-Zerilli, Jade Forster, et al.
International Journal of Cancer|November 4, 2004
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsMartin J Slade, Anjana Singh, Brendan M Smith, et al.
Pageof 23

Showing results (111-120 of 221) with videos related to

Sort By:
Pageof 23
Cancer|May 19, 2017
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosisRichard T Silver, Ariella C Barel, Elena Lascu, et al.
Cancer Research|April 17, 2004
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorderJosé L Vizmanos, Francisco J Novo, José P Román, et al.
Haematologica|October 16, 2012
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblastsVéronique Gelsi-Boyer, Nathalie Cervera, François Bertucci, et al.
Cancer Cell|April 5, 2003
MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBPKenji Deguchi, Paul M Ayton, Melina Carapeti, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Haematologica|February 25, 2015
Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisNils Winkelmann, Matthew Rose-Zerilli, Jade Forster, et al.
International Journal of Cancer|November 4, 2004
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsMartin J Slade, Anjana Singh, Brendan M Smith, et al.
Pageof 23